FDA reports serious injury in StatStrip meter recall
An October 20 FDA alert adds the agency’s most-serious-recall classification and Gen 2.0 removal guidance. The manufacturer’s advisory still differs on reported injury severity.
Original-source briefing · AI-written · Edited by Codex
Source event: 2026-07-24. Published: 2026-10-07T12:07:51.339Z. Updated: 2026-10-24T01:00:26.991Z.
What happened
Primary-source statement · An October 20 FDA alert identifies the StatStrip Glucose Hospital Meter recall as its most serious type and describes removal of affected Gen 2.0 devices until a software update becomes available. The alert lists models 63685 and 66739 and excludes the earlier Gen 1.86 generation. The underlying issue remains patient identification: Nova says previously scanned information can stay on the screen and, if accepted, attach a glucose result to the wrong medical record. [U.S. Food and Drug Administration] [Nova Biomedical]
Why it matters
Primary-source statement · The FDA says Nova reported one serious injury and no deaths associated with the issue as of October 5. Those are reported events, not independent clinical findings. Its interim instructions distinguish hospitals with an alternative device, which should stop using affected meters, from those without one, which must follow the specified precautions while awaiting a fix. Those precautions include checking identity both after scanning and on the result screen, and correcting wrongly assigned records through institutional procedures. [U.S. Food and Drug Administration]
What remains unknown
Evidence limits · Nova’s October 5 advisory still says no serious related adverse events had been reported. The FDA alert does not explain that discrepancy, so the two accounts should not be treated as identical. Nova’s notice describes a correction initiated July 24 and plans a phased software rollout in November; the reviewed documents do not establish that a fix is available. They provide no usable exposure denominator or independently verified failure rate. The linked original notices contain the complete product scope and institution-level directions; this report does not provide individual treatment advice. [U.S. Food and Drug Administration] [Nova Biomedical] [FDA-hosted company announcement]
General reporting about hospital devices for all patients, not a male-only condition. FDA and manufacturer statements are attributed and do not establish individual causation or a failure rate. Clinical teams should use the complete original notices and institutional protocols; no individual diagnosis, glucose interpretation or treatment advice is provided.
Read the infographic as text
AFFECTED DEVICES. Gen 2.0 · FDA models 63685 / 66739. Gen 1.86 is excluded.
FDA’S DATED REPORT. One serious injury; no deaths reported as of October 5.
FDA’S INTERIM GUIDANCE. Alternative device available: stop using affected meters. No alternative: follow the linked interim precautions.
SOFTWARE PLAN. A phased November rollout is planned. Availability is not established by the reviewed notices.
Evidence limit. FDA and Nova differ on reported injury severity; the records do not explain why. These are attributed reports, not a measured failure rate.
Graphic sources: U.S. Food and Drug Administration · Nova Biomedical
The developing record.
Earlier entries preserve what was published at that time; later entries may revise them.
2026-10-07T12:07:51.339Z · Initial report of the October company notice, preserving the July correction date and planned November update.
Nova flags wrong-patient glucose results in hospital meters
The newly published company notice describes a correction begun in July, affecting the Gen 2.0 system. A software update is planned for November.
What happened
In an October 5 announcement published by FDA on October 6, Nova Biomedical describes a global correction for its StatStrip Glucose Hospital Meter System that began July 24. The company says software can leave earlier patient information on the screen after a barcode scan; accepting it can assign a glucose result to the wrong medical record. Nova identifies the affected generation as Gen 2.0 and says earlier generations are unaffected. Its listed affected products include glucose-only and glucose/ketone versions, with market-specific distribution. [FDA-hosted company announcement]
Why it matters
According to Nova, an unnoticed mismatch can lead clinicians to use another patient’s result, potentially delaying care or prompting inappropriate treatment, including insulin administration. The company reports one associated U.S. adverse event, received July 17, involving inappropriate insulin administration; it says no serious related adverse events have been reported. Nova’s instructions call for checking patient identity after scanning and again on the result screen. These are the manufacturer’s hazard account, reports and instructions, not independent clinical findings or advice for an individual patient. [FDA-hosted company announcement]
What remains unknown
Nova says it has placed shipments on hold while corrective actions are developed and validated, and intends a phased software rollout in November. The notice does not establish that this update is available or its effectiveness independently verified. It gives no denominator for the reported adverse event, so a failure rate cannot be calculated from it. FDA hosting the announcement does not create a second evidence origin. Hospitals can consult the linked original for exact part numbers, distribution and interim instructions. [FDA-hosted company announcement]
2026-10-24T01:00:26.991Z · Added the FDA’s October 20 recall assessment, Gen 2.0 model scope, conditional removal/precaution guidance and dated serious-injury report; clarified the difference from Nova’s advisory. Original July event and October 7 publication remain unchanged.
FDA reports serious injury in StatStrip meter recall
An October 20 FDA alert adds the agency’s most-serious-recall classification and Gen 2.0 removal guidance. The manufacturer’s advisory still differs on reported injury severity.
What happened
An October 20 FDA alert identifies the StatStrip Glucose Hospital Meter recall as its most serious type and describes removal of affected Gen 2.0 devices until a software update becomes available. The alert lists models 63685 and 66739 and excludes the earlier Gen 1.86 generation. The underlying issue remains patient identification: Nova says previously scanned information can stay on the screen and, if accepted, attach a glucose result to the wrong medical record. [U.S. Food and Drug Administration] [Nova Biomedical]
Why it matters
The FDA says Nova reported one serious injury and no deaths associated with the issue as of October 5. Those are reported events, not independent clinical findings. Its interim instructions distinguish hospitals with an alternative device, which should stop using affected meters, from those without one, which must follow the specified precautions while awaiting a fix. Those precautions include checking identity both after scanning and on the result screen, and correcting wrongly assigned records through institutional procedures. [U.S. Food and Drug Administration]
What remains unknown
Nova’s October 5 advisory still says no serious related adverse events had been reported. The FDA alert does not explain that discrepancy, so the two accounts should not be treated as identical. Nova’s notice describes a correction initiated July 24 and plans a phased software rollout in November; the reviewed documents do not establish that a fix is available. They provide no usable exposure denominator or independently verified failure rate. The linked original notices contain the complete product scope and institution-level directions; this report does not provide individual treatment advice. [U.S. Food and Drug Administration] [Nova Biomedical] [FDA-hosted company announcement]
Read the infographic as text
AFFECTED DEVICES. Gen 2.0 · FDA models 63685 / 66739. Gen 1.86 is excluded.
FDA’S DATED REPORT. One serious injury; no deaths reported as of October 5.
FDA’S INTERIM GUIDANCE. Alternative device available: stop using affected meters. No alternative: follow the linked interim precautions.
SOFTWARE PLAN. A phased November rollout is planned. Availability is not established by the reviewed notices.
Evidence limit. FDA and Nova differ on reported injury severity; the records do not explain why. These are attributed reports, not a measured failure rate.
Graphic sources: U.S. Food and Drug Administration · Nova Biomedical
Original sources
Nova Biomedical global StatStrip medical-device correction announcement · Issuer: Nova Biomedical · 2026-10-05
FDA hospital glucose-meter removal alert, content current October 20 · Issuer: U.S. Food and Drug Administration · 2026-10-20
Nova StatStrip Customer Advisory Notice 02-26NG-US Rev. 2, October 5 · Issuer: Nova Biomedical · 2026-10-05
Corrections
2026-10-24T01:00:26.991Z: Update and clarification: the earlier version cited Nova’s October 5 statement that no serious related adverse events had been reported. The FDA’s October 20 alert reports one serious injury and no deaths as of October 5. We have added the FDA’s recall classification and model-specific guidance and made the differing severity accounts explicit. The reviewed notices do not explain their difference.